Audit of Lung Cancer Screening Practice in Chest Physicians: An Update

Lung Cancer Screening Clinical Trial

Official title:

Lung Cancer Screening Practice in Chest Physicians

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02944903
• Other study ID #: AssiutU2
• Status: Completed
• Phase: N/A
• First received: October 23, 2016
• Last updated: June 10, 2017
• Start date: October 2016
• Est. completion date: June 2017

Study information

• Verified date: June 2017
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators will conduct nationally representative survey in chest physicians in Egypt in 2016-2017. Self-administered questionnaire will be used to assess the physicians' knowledge of lung cancer screening guidelines, beliefs about the effectiveness of screening tests, and ordering of screening chest radiography, low-dose spiral computed tomography, or sputum cytology in the past 12 months.

Description:

Although current practice guidelines do not recommend screening asymptomatic patients for lung cancer, physicians may still order lung cancer screening tests. No recent national survey of health care professionals has focused on lung cancer screening

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: June 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Physicians practising in Egypt (Chest physicians, general practitioners, and general internists)

Exclusion Criteria:

• Other nationalities

• Other specialities

Related Conditions & MeSH terms

• Lung Cancer Screening
• Lung Neoplasms

Intervention

Other:
• Audit
Questionnair

Locations

Country	Name	City	State
Egypt	AssiutU	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the use of guidelines of lung cancer screening		one year
Secondary	Self- administrated questionnaire		6 months